Skip to main content

Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class Effective December 15, 2023

Last updated on

Effective December 15, 2023, the Texas Health and Human Services Commission (HHSC) will remove the non-preferred status from the generic fluticasone HFA and Qvar products on the preferred drug list (PDL).

This change allows providers to prescribe the generic fluticasone HFA and Qvar products without requiring a PDL prior authorization. This will ensure clients have access to the necessary medications.

The non-preferred status for the following drugs will be removed:

National Drug CodeDrug Name
66993007896FLUTICASONE PROP HFA 44 MCG
66993007996FLUTICASONE PROP HFA 110 MCG
66993008096FLUTICASONE PROP HFA 220 MCG
59310030240QVAR REDIHALER 40 MCG
59310030480QVAR REDIHALER 80 MCG

These changes are being made because the manufacturer of the brand-name Flovent HFA and Flovent Diskus products will discontinue them on December 31, 2023. Therefore, the preferred status of these products will not change so that all existing stock can be used. Some supplies of the products will remain available until early 2024.

Email vdp-formulary@hhsc.state.tx.us with comments or questions.